Skip to main content
. 2023 Jul 6;23:635. doi: 10.1186/s12885-023-11112-w

Fig. 3.

Fig. 3

Pooled complete response (CR) rates of short-term and long-term treatment with atezolizumab plus bevacizumab. A Pooled CR rate of long-term treatment based on Response Evaluation Criteria in Solid Tumors (RECIST). B Pooled CR rate of long-term treatment based on modified RECIST (mRECIST). (C) Pooled CR rate of short-term treatment based on RECIST. D Pooled CR rate of short-term treatment based on mRECIST